Liang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liang Xu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Damien Thompson
Department of Physics, Bernal Institute, University of Limerick, Limerick, Ireland.
8 shared publications - Shayon Bhattacharya
University of Limerick
7 shared publications - Hongbin He
Ruminant Diseases Research Center, College of Life Sciences, Shandong Normal University, Jinan, Shandong 250358, China
4 shared publications - Jie Yang
MOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics
4 shared publications Lijun Jia
4 shared publications- Min Zheng
School of Chemical Engineering, The University of Adelaide, Adelaide, Australia
4 shared publications
Latest Publications
- Open Access
- 8 August 2026
- Published by Springer Nature in Communications Chemistry
The structural basis of RanGAP1 regulation and catalysis in nuclear transport
- 8 August 2026
- Published by Springer Nature in Communications Chemistry
Open AccessThe structural basis of RanGAP1 regulation and catalysis in nuclear transport
- Open Access
The structural basis of RanGAP1 regulation and catalysis in nuclear transport
RanGAP1 promotes GTP hydrolysis of nuclear pore complex (NPC) transport complexes at the cytoplasmic face. A disordered linker connects its catalytic GAP domain to the C-terminal sumoylation domain, anchoring into NPC’s cytoplasmic filaments. This arrangement raises the question of how these distinct functions are coordinated within a crowded cellular environment. Using atomistic molecular dynamics simulations, we show that RanGAP1 adopts an autoinhibited conformation, where the C-terminal domain masks the catalytic GAP domain. Sumoylation allosterically relieves this autoinhibition, enabling GTP-bound Ran access to the GAP domain. In the cytosol, Ran-GTP/RanBP1 can bind a less populated open conformation of RanGAP1, providing a backup mechanism for GTP hydrolysis in Ran. Importantly, we observe that Arg191 of human RanGAP1 inserts into the GTP-binding pocket of Ran and directly interacts with the γ-phosphate, consistent with a canonical arginine finger. This observation contrasts with earlier models derived from yeast RanGAP and suggests that human RanGAP1 may follow a catalytic mechanism similar to classical small GTPase regulators like NF1. Together, these findings provide a framework of RanGAP1, linking autoinhibition, sumoylation, spatial organization at the NPC, and the catalytic mechanism. They also highlight how conformational regulation and post-translational modification coordinate efficient GTP hydrolysis in Ran during nuclear transport.
Open AccessThe structural basis of RanGAP1 regulation and catalysis in nuclear transport
RanGAP1 promotes GTP hydrolysis of nuclear pore complex (NPC) transport complexes at the cytoplasmic face. A disordered linker connects its catalytic GAP domain to the C-terminal sumoylation domain, anchoring into NPC’s cytoplasmic filaments. This arrangement raises the question of how these distinct functions are coordinated within a crowded cellular environment. Using atomistic molecular dynamics simulations, we show that RanGAP1 adopts an autoinhibited conformation, where the C-terminal domain masks the catalytic GAP domain. Sumoylation allosterically relieves this autoinhibition, enabling GTP-bound Ran access to the GAP domain. In the cytosol, Ran-GTP/RanBP1 can bind a less populated open conformation of RanGAP1, providing a backup mechanism for GTP hydrolysis in Ran. Importantly, we observe that Arg191 of human RanGAP1 inserts into the GTP-binding pocket of Ran and directly interacts with the γ-phosphate, consistent with a canonical arginine finger. This observation contrasts with earlier models derived from yeast RanGAP and suggests that human RanGAP1 may follow a catalytic mechanism similar to classical small GTPase regulators like NF1. Together, these findings provide a framework of RanGAP1, linking autoinhibition, sumoylation, spatial organization at the NPC, and the catalytic mechanism. They also highlight how conformational regulation and post-translational modification coordinate efficient GTP hydrolysis in Ran during nuclear transport.
- Open Access
- 8 October 2024
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 64 (20) , 8010-8023
Conformational Selection of α-Synuclein Tetramers at Biological Interfaces
Controlling the polymorphic assemblies of α-synuclein (αS) oligomers is crucial to reroute toxic protein aggregation implicated in Parkinson's disease (PD). One potential mediator is the interaction of αS tetramers with cell membranes, which may regulate the dynamic balance between aggregation-prone disordered monomers and aggregation-resistant helical tetramers. Here, we model diverse tetramer-cell interactions and compare the structure-function relations at the supramolecular-biological interface with available experimental data. The models predict preferential interaction of compact αS tetramers with highly charged membrane surfaces, which may further stabilize this aggregation-resistant conformer. On moderately charged membranes, extended structures are preferred. In addition to surface charge, curvature influences tetramer thermodynamic stability and aggregation, with potential for selective isolation of tetramers via regio-specific interactions with strongly negatively charged micelles that screen further aggregation. Our modeling data set highlights diverse beneficial nano-bio interactions to redirect biomolecule assembly, supporting new therapeutic approaches for PD based on lipid-mediated conformational selection and inhibition.
- 8 October 2024
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 64 (20) , 8010-8023
Open AccessConformational Selection of α-Synuclein Tetramers at Biological Interfaces
Controlling the polymorphic assemblies of α-synuclein (αS) oligomers is crucial to reroute toxic protein aggregation implicated in Parkinson's disease (PD). One potential mediator is the interaction of αS tetramers with cell membranes, which may regulate the dynamic balance between aggregation-prone disordered monomers and aggregation-resistant helical tetramers. Here, we model diverse tetramer-cell interactions and compare the structure-function relations at the supramolecular-biological interface with available experimental data. The models predict preferential interaction of compact αS tetramers with highly charged membrane surfaces, which may further stabilize this aggregation-resistant conformer. On moderately charged membranes, extended structures are preferred. In addition to surface charge, curvature influences tetramer thermodynamic stability and aggregation, with potential for selective isolation of tetramers via regio-specific interactions with strongly negatively charged micelles that screen further aggregation. Our modeling data set highlights diverse beneficial nano-bio interactions to redirect biomolecule assembly, supporting new therapeutic approaches for PD based on lipid-mediated conformational selection and inhibition.
- Open Access
- 30 September 2024
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 64 (19) , 7709-7724
Capturing Autoinhibited PDK1 Reveals the Linker’s Regulatory Role, Informing Innovative Inhibitor Design
PDK1 is crucial for PI3K/AKT/mTOR and Ras/MAPK cancer signaling. It phosphorylates AKT in a PIP3-dependent but S6K, SGK, and RSK kinases in a PIP3-independent manner. Unlike its substrates, its autoinhibited monomeric state has been unclear, likely due to its low population time, and phosphorylation in the absence of PIP3 has been puzzling too. Here, guided by experimental data, we constructed models and performed all-atom molecular dynamics simulations. In the autoinhibited PDK1 conformation that resembles autoinhibited AKT, binding of the linker between the kinase and PH domains to the PIF-binding pocket promotes the formation of the Glu130-Lys111 salt bridge and weakens the association of the kinase domain with the PH domain, shifting the population from the autoinhibited state to states accessible to the membrane and its kinase substrates. The interaction of the substrates' hydrophobic motif and the PDK1 PIF-binding pocket facilitates the release of the autoinhibition even in the absence of PIP3. Phosphorylation of the serine-rich motif within the linker further attenuates the association of the PH domain with the kinase domain. These suggest that while the monomeric autoinhibited state is relatively stable, it can readily shift to its active, catalysis-prone state to phosphorylate its diverse substrates. Our findings reveal the PDK1 activation mechanism and discover the regulatory role of PDK1's linker, which lead to two innovative linker-based inhibitor strategies: (i) locking the autoinhibited PDK1 through optimization of the interactions of AKT inhibitors with the PH domain of PDK1 and (ii) analogs (small molecules or peptidomimetics) that mimic the linker interactions with the PIF-binding pocket.
- 30 September 2024
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 64 (19) , 7709-7724
Open AccessCapturing Autoinhibited PDK1 Reveals the Linker’s Regulatory Role, Informing Innovative Inhibitor Design
PDK1 is crucial for PI3K/AKT/mTOR and Ras/MAPK cancer signaling. It phosphorylates AKT in a PIP3-dependent but S6K, SGK, and RSK kinases in a PIP3-independent manner. Unlike its substrates, its autoinhibited monomeric state has been unclear, likely due to its low population time, and phosphorylation in the absence of PIP3 has been puzzling too. Here, guided by experimental data, we constructed models and performed all-atom molecular dynamics simulations. In the autoinhibited PDK1 conformation that resembles autoinhibited AKT, binding of the linker between the kinase and PH domains to the PIF-binding pocket promotes the formation of the Glu130-Lys111 salt bridge and weakens the association of the kinase domain with the PH domain, shifting the population from the autoinhibited state to states accessible to the membrane and its kinase substrates. The interaction of the substrates' hydrophobic motif and the PDK1 PIF-binding pocket facilitates the release of the autoinhibition even in the absence of PIP3. Phosphorylation of the serine-rich motif within the linker further attenuates the association of the PH domain with the kinase domain. These suggest that while the monomeric autoinhibited state is relatively stable, it can readily shift to its active, catalysis-prone state to phosphorylate its diverse substrates. Our findings reveal the PDK1 activation mechanism and discover the regulatory role of PDK1's linker, which lead to two innovative linker-based inhibitor strategies: (i) locking the autoinhibited PDK1 through optimization of the interactions of AKT inhibitors with the PH domain of PDK1 and (ii) analogs (small molecules or peptidomimetics) that mimic the linker interactions with the PIF-binding pocket.
- Open Access
- 15 July 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 2818-2825
In Vivo Optogenetic Manipulation of Transgene Expression in Retinal Neurovasculature
The retina is prone to developing pathological neovascularization, a leading cause of blindness in humans. Because excess neovascularization does not affect the entire retina, global inhibition treatment of angiogenesis critically interferes with healthy, unaffected retinal tissue. We therefore established an in vivo photoactivated gene expression paradigm which would allow light-mediated targeting of antiangiogenic genetic treatment only to affected retinal regions. We synthesized a "caged" (i.e., reversibly inhibited) photosensitive 4-hydroxytamoxifen analog. Molecular docking analyses validated its reduced transcriptional activity. Caged 4-hydroxytamoxifen was intravitreally injected into mice harboring the inducible Cre/lox system, with CreERT2 being expressed via the Tie2 promoter in the neurovasculature. Subsequent in vivo irradiation of eyes significantly induced retinal expression of a Cre-dependent transgene in retinal blood vessels. Using GFAP-CreERT2 mice, successful photoactivation was also achieved in eyes and also in ex vivo brain slices for validation of the approach. This highlights the possibility of light-mediated gene therapies specific for the retina, a key first step in personalized medicine.
- 15 July 2024
- Published by American Chemical Society (ACS) in JACS Au
- Vol. 4 (8) , 2818-2825
Open AccessIn Vivo Optogenetic Manipulation of Transgene Expression in Retinal Neurovasculature
The retina is prone to developing pathological neovascularization, a leading cause of blindness in humans. Because excess neovascularization does not affect the entire retina, global inhibition treatment of angiogenesis critically interferes with healthy, unaffected retinal tissue. We therefore established an in vivo photoactivated gene expression paradigm which would allow light-mediated targeting of antiangiogenic genetic treatment only to affected retinal regions. We synthesized a "caged" (i.e., reversibly inhibited) photosensitive 4-hydroxytamoxifen analog. Molecular docking analyses validated its reduced transcriptional activity. Caged 4-hydroxytamoxifen was intravitreally injected into mice harboring the inducible Cre/lox system, with CreERT2 being expressed via the Tie2 promoter in the neurovasculature. Subsequent in vivo irradiation of eyes significantly induced retinal expression of a Cre-dependent transgene in retinal blood vessels. Using GFAP-CreERT2 mice, successful photoactivation was also achieved in eyes and also in ex vivo brain slices for validation of the approach. This highlights the possibility of light-mediated gene therapies specific for the retina, a key first step in personalized medicine.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Supplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Supplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Supplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Supplementary Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Purpose: Sensitive to apoptosis gene (SAG; also known as RBX2 or ROC2) was originally cloned as a redox-inducible antioxidant protein and was later characterized as a RING component of SCF E3 ubiquitin ligases. SAG overexpression inhibits apoptosis induced by many stimuli both in vitro and in vivo. SAG mRNA was overexpressed in human lung tumor tissues with a correlation to poor patient survival. To investigate whether SAG serves as an anticancer target, we determined the effect of SAG silencing on cell proliferation, survival, and radiosensitivity.Experimental Design: SAG protein expression in human tumors was evaluated by immunohistochemical staining using tumor tissue arrays. SAG expression in cancer cells was knocked down by siRNA silencing. The anticancer effects of SAG silencing were evaluated by in vitro assays for cell growth and survival and by an in vivo orthotopic xenograft tumor model. Radiosensitization by SAG silencing of human cancer cells was determined by clonogenic survival assay. Apoptosis induction was evaluated by fluorescence-activated cell sorting analysis, caspase-3 activation assay, and Western blotting of apoptosis-associated proteins.Results: SAG was overexpressed in multiple human tumor tissues compared with their normal counterparts. SAG silencing selectively inhibited cancer cell proliferation, suppressed in vivo tumor growth, and sensitized radiation-resistant cancer cells to radiation. Mechanistically, SAG silencing induced apoptosis with accumulation of NOXA, whereas SAG overexpression reduced NOXA levels and shortened NOXA protein half-life.Conclusions: The findings showed that SAG E3 ubiquitin ligase plays an essential role in cancer cell proliferation and tumor growth and may serve as a promising anticancer and radiosensitizing target. Clin Cancer Res; 16(3); 814–24
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
Purpose: Sensitive to apoptosis gene (SAG; also known as RBX2 or ROC2) was originally cloned as a redox-inducible antioxidant protein and was later characterized as a RING component of SCF E3 ubiquitin ligases. SAG overexpression inhibits apoptosis induced by many stimuli both in vitro and in vivo. SAG mRNA was overexpressed in human lung tumor tissues with a correlation to poor patient survival. To investigate whether SAG serves as an anticancer target, we determined the effect of SAG silencing on cell proliferation, survival, and radiosensitivity.Experimental Design: SAG protein expression in human tumors was evaluated by immunohistochemical staining using tumor tissue arrays. SAG expression in cancer cells was knocked down by siRNA silencing. The anticancer effects of SAG silencing were evaluated by in vitro assays for cell growth and survival and by an in vivo orthotopic xenograft tumor model. Radiosensitization by SAG silencing of human cancer cells was determined by clonogenic survival assay. Apoptosis induction was evaluated by fluorescence-activated cell sorting analysis, caspase-3 activation assay, and Western blotting of apoptosis-associated proteins.Results: SAG was overexpressed in multiple human tumor tissues compared with their normal counterparts. SAG silencing selectively inhibited cancer cell proliferation, suppressed in vivo tumor growth, and sensitized radiation-resistant cancer cells to radiation. Mechanistically, SAG silencing induced apoptosis with accumulation of NOXA, whereas SAG overexpression reduced NOXA levels and shortened NOXA protein half-life.Conclusions: The findings showed that SAG E3 ubiquitin ligase plays an essential role in cancer cell proliferation and tumor growth and may serve as a promising anticancer and radiosensitizing target. Clin Cancer Res; 16(3); 814–24
- Open Access
Phased Progressive Learning with Coupling-Regulation-Imbalance Loss for Imbalanced Data Classification
Deep convolutional neural networks often perform poorly when faced with datasets that suffer from quantity imbalances and classification difficulties. Despite advances in the field, existing two-stage approaches still exhibit dataset bias or domain shift. To counter this, a phased progressive learning schedule has been proposed that gradually shifts the emphasis from representation learning to training the upper classifier. This approach is particularly beneficial for datasets with larger imbalances or fewer samples. Another new method a coupling-regulation-imbalance loss function is proposed, which combines three parts: a correction term, Focal loss, and LDAM loss. This loss is effective in addressing quantity imbalances and outliers, while regulating the focus of attention on samples with varying classification difficulties. These approaches have yielded satisfactory results on several benchmark datasets, including Imbalanced CIFAR10, Imbalanced CIFAR100, ImageNet-LT, and iNaturalist 2018, and can be easily generalized to other imbalanced classification models.
Open AccessPhased Progressive Learning with Coupling-Regulation-Imbalance Loss for Imbalanced Data Classification
Deep convolutional neural networks often perform poorly when faced with datasets that suffer from quantity imbalances and classification difficulties. Despite advances in the field, existing two-stage approaches still exhibit dataset bias or domain shift. To counter this, a phased progressive learning schedule has been proposed that gradually shifts the emphasis from representation learning to training the upper classifier. This approach is particularly beneficial for datasets with larger imbalances or fewer samples. Another new method a coupling-regulation-imbalance loss function is proposed, which combines three parts: a correction term, Focal loss, and LDAM loss. This loss is effective in addressing quantity imbalances and outliers, while regulating the focus of attention on samples with varying classification difficulties. These approaches have yielded satisfactory results on several benchmark datasets, including Imbalanced CIFAR10, Imbalanced CIFAR100, ImageNet-LT, and iNaturalist 2018, and can be easily generalized to other imbalanced classification models.